OMCLOmnicell, Inc.
Price
+14%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, price roughly fair, growing in the filings, the market undecided.
Our products and services span the evolving continuum of care, including inpatient, outpatient, and retail settings. We provide a range of points of care medication and supply dispensing systems, including automated systems. We also offer advanced automation solutions including robotics designed to automate work, streamline workflows, and reduce human error. Across these settings, we provide central pharmacy automation solutions for both medication dispensing and IV compounding.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Omnicell, Inc. (OMCL) reported revenue of $312M in Q2 2026 (quarter ended Jun 30, 2026), up 7.4% from the same quarter a year earlier. That came with a gross margin of 49% and net income of $24M (7.8% of revenue). For the full year FY2025, revenue was $1.18B (+6.5% year on year) and net income $2.1M. Its largest product in Q2 2026 was Connected Devices Software Licenses And Other at $149M, 48% of the disclosed total, well ahead of Saa S And Expert Services at 22%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 30, 2026Vice President, Investor Relations.Earnings release · press release
- Jul 1, 2026On June 30, 2026, the Board of Directors (“Board”) of Omnicell, Inc. (“Omnicell” or the “Company”) appointed Mr. Nnamdi Njoku to serve as President of the Company, effective July 1, 2026.Director or officer change · Form 8-K
- May 26, 2026Amendment to the Omnicell, Inc. 2009 Equity Incentive Plan As described below under.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $312.2MThe company’s own SEC segment disclosure.
- Connected Devices Software Licenses And Other$149.2M48%
- Saa S And Expert Services$68.6M22%
- Technical Services$68.6M22%
- Consumables$25.8M8%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Health Information Services
Ranks #8 of 20 by RyuScore